[EN] BENZIMIDAZOLE AND AZABENZIMIDAZOLE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE<br/>[FR] COMPOSÉS BENZIMIDAZOLE ET AZABENZIMIDAZOLE QUI INHIBENT LA KINASE DES LYMPHOMES ANAPLASIQUES
申请人:AMGEN INC
公开号:WO2012018668A1
公开(公告)日:2012-02-09
Compounds of Formula (I) are useful inhibitors of anaplastic lymphoma kinase. Compounds of Formula (I) have the following structure: where the definitions of the variables are provided herein.
BENZOQUINOLINE INHIBITORS OF VESICULAR MONOAMINE TRANSPORTER 2
申请人:Auspex Pharmaceuticals, Inc.
公开号:US20140350044A1
公开(公告)日:2014-11-27
The present invention relates to new benzoquinoline inhibitors of vesicular monoamine transporter 2 (VMAT2), pharmaceutical compositions thereof, and methods of use thereof.
Benzimidazole and azabenzimidazole compounds that inhibit anaplastic lymphoma kinase
申请人:Boezio Christiane M.
公开号:US09115127B2
公开(公告)日:2015-08-25
Compounds of Formula (I) are useful inhibitors of anaplastic lymphoma kinase. Compounds of Formula (I) have the following structure: where the definitions of the variables are provided herein.
The invention relates to 3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives, their preparation and their use in medicine, particularly in the treatment of pain.
KINASE INHIBITORS
申请人:GB005, Inc.
公开号:US20220009920A1
公开(公告)日:2022-01-13
Disclosed herein are protein kinase inhibitors, in particular Bruton's tyrosine kinase (BTK) inhibitors, pharmaceutical compositions comprising them, processes for preparing them and uses of such protein kinase inhibitors to treat or prevent diseases, disorders and conditions associated with kinase function. In particular, the present invention relates to selective BTK inhibitors.